BR112021022527A2 - Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos - Google Patents

Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos

Info

Publication number
BR112021022527A2
BR112021022527A2 BR112021022527A BR112021022527A BR112021022527A2 BR 112021022527 A2 BR112021022527 A2 BR 112021022527A2 BR 112021022527 A BR112021022527 A BR 112021022527A BR 112021022527 A BR112021022527 A BR 112021022527A BR 112021022527 A2 BR112021022527 A2 BR 112021022527A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
zuranolone
brexanolone
ganaxolone
composition containing
Prior art date
Application number
BR112021022527A
Other languages
English (en)
Inventor
Lianhong Xu
G Strickley Robert
Zhi Hong
Original Assignee
Brii Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brii Biosciences Inc filed Critical Brii Biosciences Inc
Publication of BR112021022527A2 publication Critical patent/BR112021022527A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos das mesmas. a presente invenção refere-se a uma composição farmacêutica que compreende uma quantidade farmaceuticamente eficaz de um esteroide neuroativo que é um modulador positivo de receptores de ácido ¿ aminobutírico tipo a (gabaa). a presente invenção também se refere a métodos de tratamento de doenças que usam a composição farmacêutica e processos de produção da composição farmacêutica.
BR112021022527A 2019-05-10 2020-05-08 Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos BR112021022527A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962846576P 2019-05-10 2019-05-10
US202063018815P 2020-05-01 2020-05-01
PCT/US2020/032172 WO2020231837A1 (en) 2019-05-10 2020-05-08 Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof

Publications (1)

Publication Number Publication Date
BR112021022527A2 true BR112021022527A2 (pt) 2021-12-28

Family

ID=73288816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022527A BR112021022527A2 (pt) 2019-05-10 2020-05-08 Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos

Country Status (13)

Country Link
US (1) US20220241295A1 (pt)
EP (1) EP3965772A4 (pt)
JP (1) JP2022532710A (pt)
KR (1) KR20220006565A (pt)
CN (1) CN113939299A (pt)
AU (1) AU2020275291A1 (pt)
BR (1) BR112021022527A2 (pt)
CA (1) CA3138901A1 (pt)
IL (1) IL287905A (pt)
MX (1) MX2021013695A (pt)
SG (1) SG11202112111WA (pt)
TW (2) TW202344255A (pt)
WO (1) WO2020231837A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295902A (en) * 2020-02-27 2022-10-01 Brii Biosciences Inc Drug inhibitors of neuroactive steroids
CA3190436A1 (en) * 2020-08-17 2022-02-24 Brii Biosciences, Inc. Pharmaceutical composition containing neuroactive steroid and use thereof
CN112516086B (zh) * 2020-12-08 2022-05-20 武汉久安药物研究院有限公司 注射用布瑞诺龙脂肪乳及其制备方法
WO2022155507A1 (en) * 2021-01-15 2022-07-21 Jubilant Pharma Holdings Inc. Transmucosal dosage forms of brexanolone
WO2023092046A1 (en) * 2021-11-18 2023-05-25 Brii Biosciences, Inc. Process and therapeutic composition for treating and preventing severe injection site reactions
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2024085245A1 (ja) * 2022-10-21 2024-04-25 国立大学法人高知大学 術後せん妄の抑制薬
CN115957332B (zh) * 2022-11-01 2023-10-10 北京华睿鼎信科技有限公司 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101405545B1 (ko) * 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도
EP3253418A1 (en) * 2015-02-06 2017-12-13 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
JP2018530585A (ja) * 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド ナノ粒子を含む注射可能な神経ステロイド製剤
US20180296487A1 (en) * 2017-04-18 2018-10-18 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations

Also Published As

Publication number Publication date
MX2021013695A (es) 2022-01-26
JP2022532710A (ja) 2022-07-19
TWI793419B (zh) 2023-02-21
CA3138901A1 (en) 2020-11-19
SG11202112111WA (en) 2021-11-29
EP3965772A1 (en) 2022-03-16
US20220241295A1 (en) 2022-08-04
EP3965772A4 (en) 2023-05-10
IL287905A (en) 2022-01-01
TW202108146A (zh) 2021-03-01
TW202344255A (zh) 2023-11-16
CN113939299A (zh) 2022-01-14
AU2020275291A1 (en) 2021-11-25
KR20220006565A (ko) 2022-01-17
WO2020231837A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
BR112021022527A2 (pt) Composição farmacêutica contendo brexanolona, ganaxolona ou zuranolona e usos dos mesmos
BR112021015238A2 (pt) Novos anticorpos de ligação a cd40
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
BR112019006216A2 (pt) compostos de p2x3 e/ou p2x2/3 e métodos
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112022013322A2 (pt) Derivado de tetra-hidroisoquinolina tricíclico, método de preparação para o mesmo e aplicação do mesmo em medicina
EA201890590A1 (ru) Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
BR112023019967A2 (pt) Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização